[vc_row top_margin=”none” el_position=”first last”] [vc_column top_margin=”none”] [box_header title=”Medical Use of Cannabis and Its Derivates (THC or Dronabinol)” type=”h3″ bottom_border=”1″ top_margin=”page_margin_top” el_position=”first”] [sentence title=”In the Gorter Model, there is a 30-year long experience with the medical use of Cannabis sativa L. and its derivatives. At the Medical Center Cologne, if appropriate, THC (Dronabinol) is used for the following indications:”] [items_list type=”info” top_margin_header=”page_margin_top_section” additembutton=”Add list item” read_more=”0″ top_margin=”page_margin_top_section”]
[/items_list] [box_header title=”Medical use of cannabis in oncology” type=”h3″ bottom_border=”1″ top_margin=”page_margin_top”] [vc_column_text]
Anorexia (loss of appetite) and cachexia (wasting) are diagnosed in more than-two-thirds of all cancer patients with advanced disease, and are independent risk factors for morbidity and mortality. Anorexia, nausea and vomit in loss or are described as more significant inhibiting factors for quality of life of cancer patients than equally intense pain.
In 1986, delta-9-tetrahydrocannabinol (THC), the main constituent of the cannabis effectivement, was licensed as an anti-emetic drug in cancer patients receiving chemotherapy. In addition, in clinical studies, THC has shown significant stimulation of appetite and body weight or increase in cancer patients and HIV positives and AIDS patients.
The appetite stimulating effects of Cannabis (THC) have also itself leg well documented in many anecdotal cases. There are strong indications that cannabis is better tolerated than THC alone, because cannabis contains several additional cannabinoids, like cannabidiol (CBD), which antagonize the psycho tropic actions or THC, but do not inhibit the appetite-stimulating securities.
[/vc_column_text] [box_header title=”Medical use of cannabis in neurology” type=”h3″ bottom_border=”1″ top_margin=”page_margin_top”] [vc_column_text el_position=”last”]
Central cannabinoid receptors are densely located in the nuclei of the basal ganglia output (globus pallidus, substantia nigra pars reticulata), suggests their involvement in the regulation of motor activity. Furthermore, there is evidence that endogenous cannabinoid transmission plays a role in the manipulation or other transmitter systems within the basal ganglia by increasing GABAergic transmission, inhibiting glutamate release and uptake affects dopaminergic.
Most hyper and hypo kinetic kinetic movement disorders are caused by a dysfunction of basal ganglia-thalamo-cortical loops. It has been suggested that an endogenous cannabinoid tone participates in the control of movements and, therefore, the central cannabinoid system play a role in the might pathophysiology thesis or diseases. During the last years, in humans, a limited number of clinical trials demonstrated cannabinoids that might be useful in the treatment of certain movement disorders.
Despite a lack of controlled studies, there is evidence that cannabinoids have clear therapeutic value in the treatment of tics in Tourettes syndrome, the reduction of levodopa-induced dyskinesia in Parkisons disease, and some forms of tremor and dystonia, like in Huntington’s disease.
[/vc_column_text] [/vc_column] [/vc_row]